(1) Consistent with the protocols adopted by the State Board of Pharmacy by rule, as recommended by the Public Health and Pharmacy Formulary Advisory Committee, a pharmacist may test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prescribe, dispense and administer treatment, including drug therapy, for SARS-CoV-2. (2) When testing for SARS-CoV-2, a pharmacist may use: (a) A screening procedure that can be safely performed by a pharmacist; and (b) A test that: (A) Guides the pharmacists clinical decision-making; (B) Is determined by the Centers for Medicare and Medicaid Services to qualify as a waived test under the Clinical Laboratory Improvement Amendments of 1988 (P.L. 100-578, 42 U.S.C. 201 and 263a) or federal regulations adopted pursuant to the Clinical Laboratory Improvement Amendments of 1988 or is approved by the United States Food and Drug Administration; and (C) Is approved by the board by rule for use under this section. (3) A pharmacist may delegate to a pharmacy technician or an intern under the pharmacists supervision the administrative and technical tasks of performing a task described in subsection (2) of this section. (4) The board may adopt rules as necessary to carry out this section.
‹ Prev All Oregon sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.